OncoMatch/Clinical Trials/NCT04192344
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Is NCT04192344 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ABSK021 for neoplasms.
Treatment: ABSK021 — This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CSF-1/CSF-1R pathway inhibitor
Exception: not applicable for TGCT patients in US (expansion part only)
Previous treatment with CSF-1(colony stimulating factor 1)/CSF-1R (colony stimulating factor 1 receptor) pathway inhibitors
Cannot have received: chemotherapy (nitrosourea, mitomycin)
chemotherapy with nitrosourea or mitomycin should be 6 weeks prior to initiation of study treatment
Cannot have received: chemotherapy
Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment
Cannot have received: radiotherapy
Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment
Cannot have received: endocrine therapy
Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment
Cannot have received: molecular targeted therapy
Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment
Cannot have received: corticosteroid
Prior corticosteroids as anti-cancer therapy within a minimum of 2 weeks of the first dose of study drug
Lab requirements
Blood counts
bone marrow function
Kidney function
Liver function
Cardiac function
Impaired cardiac function or clinically significant cardiac disease excluded
Adequate organ function and bone marrow function; Impaired cardiac function or clinically significant cardiac disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Precision NextGen Oncology · Beverly Hills, California
- SCRI at HealthOne · Denver, Colorado
- The Winship Cancer Institute of Emory University · Atlanta, Georgia
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify